According to I-Mab Biopharma's latest financial reports the company's current revenue (TTM) is HK$0.28 B. In 2022 the company made a revenue of -HK$0.25 B a decrease over the revenue in the year 2021 that were of HK$0.10 B.The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.